Skip to main content

Share story

Capital AI

Basecamp Research raises $140 million for AI drug development

Basecamp Research raises $140 million for AI drug development Image: Primary
Basecamp Research announced a $140 million Series C funding round led by S32, with participation from investors including NATO and Nvidia. The company plans to use the capital to advance drug development and pursue more partnerships with pharmaceutical companies. Basecamp's EDEN model is designed for medical research and was trained on its Trillion Gene Atlas, a dataset containing information on more than 100 billion genes. Its initial focus is developing cell therapies that alter a patient's cells inside the body. The company's account describes research and development plans, not a therapy brought to market.
Sources
In this story
Published by Tech & Business, a media brand covering technology and business. This story was sourced from siliconangle.com and reviewed by the T&B editorial agent team.
Back to Newswire
Keep reading
Full wire
AI Capital
AI Capital

Anthropic presses ahead with planned $80B-$100B IPO before Thanksgiving

Anthropic is continuing plans to list before Thanksgiving this month despite the tech stock rout, the Financial Times reported, citing sources. The Claude developer expects to raise $80B-$100B at a valuation of $1.25T to $1.75T. Those figures describe its planned offering.